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ABSTRACT
Mastitis is a major cost for the dairy sector, leading to an estimated loss of 
$177 per cow from reduced milk production, treatment and increased culling. When 
quality and yield loss for the processing sector are added, the cost to the New York 
industry is nearly $200 million annually.
This paper evaluates two promising new technologies, a bactericidal protein 
treatment and a vaccine. Both have shown effectiveness in preliminary trials against 
a major source of infection. Assuming that further development will allow products 
effective against the major bacterial source of infection, the products are projected to 
save the New York industry $18.7 and $50.9 million annually, respectively. The 
bactericidin will reduce or replace antibiotic usage, a desirable goal in the opinion of 
many, but the vaccine promises to reduce the significant management currently 
required to control the disease.
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ECONOMIC LOSSES TO NEW YORK’S DAIRY SECTOR DUE TO MASTITIS
Heiko Frick and William Lesser*
Introduction
Mastitis has been considered the number one dairy disease for many years. 
Although much research effort and funds have been spent to gain knowledge of the 
etiology and control of mastitis, the disease remains a substantial problem. Indeed, 
little real advance has been made in mastitis control following the advent of 
antibiotics and improved management practices going back to the World War II era. 
Now biotechnology promises treatment breakthroughs which could reduce mastitis 
levels substantially and be a major economic boon to dairy farmers and milk 
processors. This paper analyzes two promising new developments, the use of bacterial 
proteins and of a mastitis vaccine. The economic implications of these new 
developments are evaluated in the latter sections of the paper. To set the stage for 
that analysis, the earlier sections contain a review of the mastitis literature, 
culminating in a projection of the costs of mastitis to the New York dairy sector in 
1988.
Etiology of Mastitis
Mastitis is an inflammation of the udder’s milk secreting tissue caused by 
bacterial infections. The four most common bacteria - Staphylococcus aureus. 
Streptococcus agalactiae. Streptococcus dvsealactiae. and Streptococcus uberis - cause 
90-95% of all infections^30). The first two bacteria types are contagious and are 
spread by infected cows; the latter two are present in the environment and on the 
cow’s body (tongue, mouth, skin). Another form of environmental bacteria, E, coli. is 
found in bedding.
* Research Associate and Associate Professor, respectively, Department of Agricultural 
Economics, Cornell University.
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Udder infections are characterized by a three step sequence^:
a) Contamination of teat end by pathogen,
b) Penetration of teat orifice and teat canal,
c) Establishment within mammary gland tissue.
The cow’s natural defenses against bacterial entrance into the teat are (1) 
through closing the teat canal tightly with the teat sphincter muscle, and (2) by layers 
of keratin lining the teat canal. Nevertheless, bacteria may gain entrance by 
colonizing, injury, and mechanical propulsion from milking machines. Once inside the 
udder, the bacteria are in a favorable growth environment.
Mastitis is a difficult cattle disease to control. It cannot be eradicated and can 
prevent dairy cows from reaching their full genetic potential. A major treatment 
breakthrough came in 1945 through the widespread use of penicillin. Since then all 
advances have been through improved hygiene and management practices. By 1968 
dry cow therapy and teat dipping had gained widespread acceptance through its dual 
mechanism: treatment of lactating cows at drying off with antibiotics to reduce the 
duration of mastitis and prevent new infections, and daily post-milking teat dipping to 
reduce infection rates.
Dairy scientists have long recognized the severity of the disease but quick and 
easy farm milk tests were required to convince farmers of the nature of the problem. 
Mastitis has been endemic but was not recognized as a problem at low levels of 
infection. The advent of the somatic cell count (SCO) has enabled farmers to 
determine the degree of infection of their herds. The SCC is a measure of white blood 
cells (leukocytes and neutrophils), the natural defense mechanism against infection, in 
milk in addition to the normal number of epithelial (glandular) cells. Most measures 
of SCC are made on bulk tanks because of the expense of individual tests, but 
increasingly whole herds are monitored on a per cow basis. Using the SCC, general
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levels of subclinical and clinical infections have been identified, as described in Table
1.
Table 1: Levels of Infection as Measured bv SCC
SCC/ml infection cell types
< 100,000 normal milk 85% epithelial - 15% white blood
500,000 subclinical 48% " - 52%
> 1,000,000 clinical 26% ” - 74% "
Source: 2
At less than 100,000 cells no infection is evident. As the SCC increases the 
likelihood of infections increases; a clear distinction between un infected^) and 
subclinically infected cows is reported between SCC’s of 150,000 to 214,000. These 
levels are subject to high cow-to-cow variations. Subclinical mastitis is not evident to 
farmers but clinical mastitis is recognized by clotted milk, body heat, redness, and 
swelling and pain in the udder.
An inherent problem in the analysis of SCC is that milk of cows with clinical 
symptoms is usually separated from the bulk tank, resulting in a lower (biased) 
inference of the degree of herd infection from bulk tank SCC samples. Although the 
SCC has been refined as a measure of likelihood of infection, the classification of a 
clinical case of mastitis is still predominantly based on visual signs. This is due in 
part to only a 70% accuracy in measuring contagious mastitis infections by milk 
c u ltu re ^ ) .
White blood cells contain proteases, lipases, and phospholipases which break 
down two important milk components, casein and milk fat, into smaller compounds 
that are more readily lost into whey during cheesemaking. Infections also damage the 
mammary epithelial tissue and result in greater plasma leakages from blood vessels. 
Blood plasma also contains lipolytic and proteolytic enzymes which similarly break 
down milk protein and fat. Lipase increases milk rancidity^28).
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Contagious Mastitis
Contagious mastitis (Staphylococcus aureus and Streptococcus agalactiae) were 
responsible for 45% and 44% respectively of all infections in a Mississippi State 
survey^33a .^ Contagious infections occur during milking when bacteria are spread 
through "contaminated washing and drying cloths, wash water, hands of operator, and 
milking machines. Because these infections are passed from animal to animal they can 
be eliminated from a herd. The Ohio Agricultural Research and Development Center 
Herd (OARDCH) had been Streptococcus agalactiae free for seven years and 
Staphylococcus aureus only existed at a 1% level^37l  In Denmark Streptococcus 
agalactiae has been reduced to 1%; other bacteria infect 35% of the cows^29l  During 
the late fifties and early sixties the New York State Mastitis Control Program had 
herd infection rates of 23% Streptococcus agalactiae and 13% Staphylococcus 
aureus^ l  (Participation in this program was mandatory for excessively poor 
producers but many better-than-average producers joined voluntarily).
Staphylococcus aureus can be controlled only with penicillin (a 70% reduction 
appears possible over 3 years) but not eradicated from a herd. Streptococcus 
agalactiae on the other hand can be eradicated. Several steps may be followed to 
reduce the spread of infection. These include udder washing with a sanitizing 
solution, and drying with individual paper towels. Milk equipment and milkers’ hands 
are important means of spreading contagious bacteria. Few milkers wear rubber 
gloves and dip them into a sanitizing solution because it is inconvenient. Changes in 
milking equipment have resulted in better liner design to avoid milk cup slipping and 
better pulsator and controller action to decrease the stress on the teat sphincter and 
reduce the likelihood of bacteria being propelled into the teat towards the end of 
milking.
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Only 40% of all infections are serious enough to be recognized as clinical and 
treated with antibiotics during lactation^, Milk from antibiotic-treated cows must be 
withheld for 36-96 hours, depending on the antibiotic. The success rate of lactation 
treatment is estimated at 40-70%, as it is effective primarily for Streptococcus 
agalautiae.(22^3) £)ry cow therapy (treating all 4 quarters of each cow at drying off) 
has proven more successful than lactation treatment with an estimated success of 70- 
98%(22). Treatment efficaiy data obtained from a New York field experiment showed 
lactation treatment response as follows: Staphylococcus aureus 28%, Streptococcus 
aealactiae 86% - dry treatment: Staphylococcus aureus 64%, Streptococcus agalactiae 
100%. Milk loss to an infected quarter is estimated at 25-60% over a lactation with 
only 5% compensated from the opposite uninfected quarter.
Environmental Mastitis
Streptococcus dvsealactiae. Streptococcus uberis. and E, coli are ubiquitous in 
the cow’s environment and serve as a common source of infection. They are extremely 
heterogeneous, each group including several species and strains. Infection-level data 
are sketchy. During the late fifties and early sixties the New York State Mastitis 
Control Program had herd infection rates of 13% for Streptococcus non-agalactiae^ 1^ . 
Two to three decades ago the frequency of E.coli was 2-3% of mastitis infections. In 
the OARDCH, streptococcal infections never exceeded 5% of quarters and coliform 
infections ranged between less than 1% to a maximum of 3% of quarters^).
Simultaneous infections of Streptococci and coliform comprise a small 
percentage of all environmental infections. Streptococcal infections peaked in summer 
and fall, accounted for 30.2% of all clinical infections in the OARDCH, exhibited 
clinical symptoms in 53% of all cases, had an average duration of 17.0 days, and 
responded to antibiotic treatment 41.7% of all times. Coliform infections peaked 
during the summer, accounted for 31.8% of all clinical infections in the OARDC herd,
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exhibited clinical symptoms in 81% of all cases, had an average duration of 9.1 days, 
and responded to antibiotic treatment 22.4% of all times. Treatment effectiveness data 
for New York were as follow s^); lactation treatment: Streptococcus dvsgalactiae 
90%, Streptococcus uberis 72% - dry treatment: Streptococcus dvsgalactiae 98%, 
Streptococcus uberis 88%. Since the symptoms of environmental mastitis are more
likely to be clinical than for contagious mastitis, farmers are more aware of the 
problem and more likely to respond through management changes.
Dry cow therapy has an effect on Streptococci but not on coliform. With the 
eradication of Streptococcus aealactiae and the reduction of Staphylococcus aureus it 
is feared that the prevalence of environmental mastitis will increase^^. Poorer 
hygiene because of denser housing is the basis of the concern. Monitoring 
environmental bacteria through SCC has not proven reliab le^). Teat dip and dry 
cow therapy (TDDCT) practice is least effective against the group E. coli. The rate of 
infection is higher in the late dry period with elevated levels of both Streptococci and 
coliform during the immediate prepartum period. Suggested control methods are 
entirely based on better hygiene and sanitation. That is, successful immunization does 
not yet exist.
Apart from infection levels, the SCC can be influenced by age of cow (increase 
of 100,000 cells each lactation), the stage of lactation (high at calving and drying off 
and low during mid lactation), season (higher in summer), and stress level^^.
Costs of Mastitis - Literature Survey Results
Infection Levels and Lost Milk Production
Past studies have identified a relationship between infection levels and lost 
milk production, a major source of costs associated with mastitis infections. Several 
standards have been devised for reflecting the relationship between infection levels 
and milk production losses. The most commonly used is the California Mastitis Test
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(CMT) which classifies the degree of infection into five categories: N-Negative, T- 
Trace, and 1, 2, 3. Table A-l in the Appendix indicates the relationship between the 
CMT, SCC and lost milk production. Losses run from close to zero for a SCC below
100.000 to 25 percent for a SCC close to three million. One aspect of lost milk 
production is the reduction of the lactation cycle by 16.6 +/- 8.4 days^2^ .
In recent years the Linear Score has emerged as a more common method of 
relating infection levels to losses in milk production. Appendix Table A-2 summarizes 
the relationship between the Linear Score (LS) and production losses. The LS runs 
from 1 to 9.
These composite tables mask the great variability in the relationships found in 
individual studies. The variability is traceable in part to the differences between 
comparisons of affected/unaffected quarters in the same animal and 
infected/uninfected udders of different animals. No conclusions as to the bacterial 
agent can be made from average SCC levels, particularly when the level is below
200.000 <32).
Discarded milk applies only to cases of clinical mastitis. Natzke calculates it 
by using a milk production level of 60 lbs, multiplies this by average withholding time 
of 5 days, and a $10/cwt value of milk which results in a cost of $30/clinical case. He 
assumes an average rate of clinical cows of 1.25 in a 100 head herd. Dobbins 
calculates it by using the milk production level at infection (35 lbs vs 45 lbs for 
healthy cows), multiplies this by average withholding time of 4 days, average number 
of infections per cow per year, and $10.50/cwt value of milk.
Natzke assumed that, at a cost of $20/visit, one in 40 clinical cases is attended 
by a veterinarian. Dobbins found that in his herds there was an average of two one- 
hour emergency calls each month for mastitis alone and the veterinary charge was 
$30/hour.
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In Natzke’s calculations 2 1/2 tubes of antibiotic are used in each treatment 
which gives a cost of $2/cow/treatment period. Dobbins found that an average of 5 
clinical cases/100 cows occurred each month which were treated twice on 2 quarters.
Natzke stated that extra labor requirements were 75 minutes per cow at a labor 
cost of $4/hour. Dobbins found that labor cost $2.50/hour and that 15 minutes/day 
were required per infected cow during the 4-day treatment period.
Natzke gave a range for culling due to mastitis of 9-17%. He continued by 
assuming a 12% average rate which, at a 25% total culling rate, corresponds to 3 
cows/100 head/year. He continued to state that the actual net replacement cost is 
$367/cow. Dobbins had found that 15 cow/100 head were culled each year for 
mastitis alone and that the net replacement cost was $260/cow.
Off-Farm Costs
Costs of mastitis to processors include lower quality due to high SCC, reduced 
fat and antibiotic adulteration of milk. When milk is picked up at the farm (which 
occurs every 1-2 days), a milk sample is taken to be analyzed for antibiotic 
contamination, SCC, and milk fat content. Antibiotic analysis requires about 30 
minutes during which the milk truck must wait. If the milk tests negative for 
antibiotics the load will be emptied into larger holding tanks. If it tests positive the 
milk will be stored separately, the test repeated, and if still positive the milk will be 
discarded. ■ ■ ■ : r
Antibiotic in milk presents several problems: the bacterial starter culture for 
cheese and yoghurt is inhibited, producing dairy products of variable and generally 
lower quality. Antibiotic contaminated milk and dairy products cannot be sold for 
human consumption.
High SCC levels cause losses in cheese production even in the absence of 
antibiotic contamination. The effect can be determined from the Van Slyke formula
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which establishes a linear relationship between the fat and casein levels of milk and
the theoretical yield of Cheddar cheese^. The relationship between the CMT and
milk fat loss is summarized in Table 2
Table 2: Relationship between CMT and Milk Fat Losses
CMT milk fat losses
study: A B
N 0 0
T 2.1% 3.4%
1 2.6% 6.9%
2 5.4% 10.3%
3 10.8% 13.7%
Sources: A 1 B 29
No decrease in casein is reported up to a SCC of 1,000,000^*^. However, as the 
SCC increases more casein is broken down into smaller compounds. The degree of 
decomposition cannot be measured with current techniques. Preliminary tests indicate 
that there is a sudden 1% drop in cheese yield as the SCC surpasses 100,000 due to 
enzymatic activity. Between 200,000 and 1,300,000 cells the decrease in yield is more 
gradual, in the range of 1-2%^. Casein comprises about three quarters of milk 
proteins^1
Milk Quality as measured by SCC and USDA regulations requires a SCC level 
below 1,000,000 cells/ml. In New York, if producers continually exceed this threshold 
they are required to participate in New York’s Mastitis Control Program. Producers 
are encouraged by some buyers to supply milk with low SCCs through premium 
payment schemes. Processors prefer constant SCCs because products will be more 
uniform and higher in both yield and quality and have longer shelf lives.
On-Farm Costs
On-farm costs have been broken down into seven categories. Three studies 
have used these categories to estimate actual costs per cow and year. Blosser (1977)
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conducted a nationwide survey in which he asked one competent person in each state 
to give a "judgement" of the costs of mastitis in that state. Dobbins (1977) used data 
from 31 random herds under the Georgia Quality Milk Program which had started a 
mastitis control program. Natzke (1976) used the Florida Agricultural Station 
Experimental herd to keep a detailed account of costs. The following table 
summarizes losses averaged by cow in herd per year:
Table 3: Average annual cost per cow due to mastitis
Study
A B c
1 reduced milk production $81.32 na $118.44
2 discarded milk $12.88 $ 6.13* $7.72
3 cost of veterinary services $ 1.97 $ 0.62 $7.20
4 cost of drugs $ 3.86 $ 2.50 $2.16
5 increased labor $ 2.28 $ 5.00 $1.50
6 decreased cow sale value
7 incr. cow replacement cost
$ 5.72 
$ 9.32 >^$11.01 >^$39.00
sum $117.35 $176.02
Source: A Blosser 4, B Natzke 20, C Dobbins 8 * = interpolated
na-not available
Reduced milk production is estimated by comparing milk production at a given 
or estimated average herd SCC to a potentially attainable SCC of 100,000. The 
number of pounds are then multiplied by a $/cwt value of milk. As is apparent from 
Table 2, the value of reduced milk production is the most important loss category. It 
should, however, be realized that the actual values may be subject to large errors 
depending on which research results the loss is based on.
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On-Farm Losses
Losses are computed from the same seven categories shown in Table 3. The 
authors assume a yearly average SCO of 400,000 cells for New York. This is based on 
a lower limit as indicated by New York DHI records which recorded levels of 373,000 
(1986) and 336,000 (1987)^^. About 25% of New York’s cows are registered in DHI. 
The average milk production for this group was 3,600 lbs higher than the state average 
which is generally assumed to indicate better management, better feed, and lower 
mastitis infection levels. In addition, SCC ranges obtained from three large New York 
cooperatives indicate average levels between 409,000 and 440,000, For another study, 
monthly SCCs were measured for seven cheese plants in Southern New 
York/Pennsylvania and six in Northern New York and New England; yearly average 
counts were 367,000 and 402,000^.
For the calculations in this study, milk production losses are based on SCCs. 
From Table A-l, a 9% loss in milk production is obtained when the SCC is 400,000. At 
a 12,401 lbs per cow average production for New York, a 9% reduction in milk 
production is equivalent to 1226 lbs, which corresponds to $143.69/cow/year at a 
projected Federal order #2 blend price for 1988 of $11.72^^ per cwt. For 
comparative purposes, which lend support to the given calculations, the reduced milk 
production at an average linear score of 4 is given (compare to Table A-2). At a 
linear score of 4 it is estimated that 1,200 lbs/lactation or 1,138 lbs/year less milk is 
produced. Translating these figures by using Table 4, it can be concluded that the 
degree of subelinical infection is in the vicinity of 50% of all cows in New York. 
This relationship measures the level of subelinical infections since milk from clinically 
infected cows usually does not enter the bulk tank.
Estimated Current Losses in New York State in 1988
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Table 4: Relationship of SCC and Per Cent Cows Infected
Bulk Tank Per Cent Cows Infected
SCC Pennsylvania study Cornell study
0- 99,000 6% 5%
100,000-199,000 17% 12%
200,000-299,000 34% 33%
300,000-399,000 45% 38%
400,000-499,000 51% 58%
500,000-599,000 67% ■ 53%
over 600,000 79% 61%
Source: 28
For the next five loss categories the following assumption applies: the 
occurrence rate (first time and subsequent infections) is set at 5% per month (i.e. 5 
cows exhibit clinical mastitis symptoms and are treated in a 100 head herd each 
month). At a 6.6 day duration interval, the total number of days/year that milk is 
discarded in a 100 cow herd is 396 days. This 5% value is justified by considering the 
range indicated by other studies. The upper range is derived from a six year study of 
clinical mastitis in a 1500 cow herd in Florida that had an average number of 2.2/100 
(st.d. 0.7) cows with clinical cases at any point in tim e^ ). Hence for a 100 cow herd 
the total number of cow days with milk discarded is 803 (2.2x365 days) a year. That 
is twice the level assumed for this study for an occurrence rate of 10%/month. The 
average duration of milk withheld was 6.6 days^^. A lower bound is given by a 
study on selective New York DHI herds which participated in a regular veterinary 
program at Cornell University. It was found that an incidence level (number of first 
time clinical infections) of 9. 3% prevailed^). This level compares to, 16.8% in 
O ntario^. When applying another study which gives a relationship between mastitis 
occurrence in a lactation and parity (number of calves the cow has had) for Holstein 
cows, the incidence rates of these two studies translate into occurrence rates of 1.7% 
and 3.7%e®). It must be noted that these lower bounds apply to better-than-average 
herds.
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Discarded milk is set at 40 lbs/day (12,401 lbs production/305 day lactation 
period) while the infection is acute and the cow is being treated. Since there are 396 
days/year in a 100 cow herd during which milk is discarded, the loss of milk which is 
non-usable is equivalent to 158 lbs per cow/year or $18.50/cow/year at $11.72/cwt. 
This milk is fed to calves, reducing milk replacer costs by $9.48 (1 lb of replacer for 
10 lbs of milk at $30 per 50 lbs of replacer). The net cost of discarded milk is 
$9.08/cow/year ($18.50-9.48).
Cost of veterinary services is based on 60 (5 x 12 month) clinical incidents a 
year. An estimated 10% of clinical cases are treated by veterinarians at an average 
cost of $30 per case^ . The resulting cost is $1,80 per cow/year.
Cost of drugs used is calculated by assuming a $1.00/treatment tube 
administered twice to an average of three quarters in 60 cows. The cost per cow and 
year is $3.60.
Increased labor required to milk and treat mastitic cows separately is estimated 
at 1/2 hour for each case per day for 6.6 days. Total days is assumed again at 396 
days. Labor cost is taken at $4.00 an hour. The resulting cost per cow and year is 
$7.92.
The difference in decreased sale value per cow for slaughter and cost of a 
replacement is estimated at $275/culled cow^®\ This is based on an average slaughter 
price of $42/cwt, an average slaughter weight of 1350 lbs and a replacement cost of 
$850. New York DHI records indicate a cull rate attributable to mastitis of 4.0% 
(st.d.3.45)^®\ The average culling/replacement cost is therefore $11.00 per cow and 
year. Culling and replacement costs vary depending on beef prices. During the first 
half of 1988 they were very high especially compared to the price of milk.
Table 5 summarizes current losses in New York State averaged per cow in herd 
per year.
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Table 5: Milk Losses in New York State due to Mastitis
1 reduced milk production $143.69
2 discarded milk $ 9.08
3 cost of veterinary services $ 1.80
4 cost of drugs $ 3.60
5 increased labor $ 7.92
6 decreased cow sale value )$ n .o o
7 incr. cow replacement cost /
sum ' $177.09
Source: see text
The estimated total loss of $177.09/cow is comparable to earlier estimates given 
in Table 3; only reduced milk production and culling/replacement costs vary 
significantly from the earlier studies. The higher loss value today appears attributable 
to two factors: higher milk output per cow increases total loss per cow and a higher 
price of milk magnifies the physical loss.
Independently of this study, researchers at Ohio State University collected data 
on herds in Ohio to calculate the cost of mastitis^ They concluded that 80% of the 
total results from decreased milk production. In their calculations they arrived at an 
average of 1,200 lbs of milk lost/cow/year compared to 1,226 lbs used in this study. 
The cost/cow/yeaf was $186.13, based on a milk price of $12.60/cwt.
A loss of $177.09/cow/year corresponds to $151,943,220 for the New York’s 
entire dairy farm sector when multiplying the per cow loss by the January 1, 1988 
USDA inventory estimate of 858,000 cows in New York State^17 .^
Off-Farm Losses
Off-farm losses apply to the milk processing industry. More milk is processed 
in New York than is produced there. As a result losses to the processing industry are 
based on a larger volume.
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Milk adulterated with antibiotics is the most apjparent loss which occurs at the 
processing stage. Farmers generally do not receive payments for such milk. From a 
survey conducted for this study the weighted adulterated milk losses are estimated at 
0.1% of milk receipts. Given that milk received at New York dairies in 1986 was
14.884.751.000 Ibs^2^  and the projected blend price is $II.72/cwt, losses due to 
antibiotic adulteration amount to $1,750,000 in total. Milk testing for adulteration is a 
cost which processors incur but is not applied in this study.
Losses to the cheesemaking industry can be broken down into two categories: 1) 
lost fat production due to a decrease in fat yield and 2) damage due to enzymatic 
breakdown. At a SCC level of 400,000 an averaged fat loss of 3.5% can be 
interpolated from Table 2. Lipolytic breakdown has not yet been quantified but 
proteolytic breakdown at 400,000 cells is in the vicinity of 2% reduced cheese yield.
Losses may be computed as follows: at an average fat production level of
3.66% ^’ a 3.5% loss is equivalent to an absolute percent fat reduction of 0.13% or
19.350.000 lbs. Applying the butterfat price differential, this loss of 0.13% butterfat 
translates into a dollar value of about $30,000,000 (based on 14,884,751,000 lbs of milk 
at $11.72 and 3.66% butterfat compared to the same quantity at $11.92 and 3.79% 
butterfat).
In calculating cheese losses resulting from proteolytic decomposition, a 2% 
difference in production at 450,000,000 lbs of cheese produced in New York amounts 
to 9,000,000 lbs annually. The Cheddar cheese price for 40 lbs blocks quoted at the 
National Cheese Exchange is used as an indicator for losses to cheese manufacturers. 
For 1988 this average is expected to be about $1.15/lb. Losses to the cheesemaking 
industry are hence around $10,350,000/year.
Losses due to inconsistent quality are too ephemeral to be quantified but are a 
considerable concern to processors. For fluid milk, significant correlations have been
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found between SCC and flavor scores but these two cannot be quantified for this 
s tu d y ^ V  Table 6 summarizes the quantifiable losses:
Table 6: Summary of Economic Losses in 1988 to New York’s Dairy Sector
On Farm $ 151,943,000
Milk Adulteration $ 1,750,000
Reduced Fat $ 30,000,000
Reduced Cheese $ 10,350,000
Total ' $ 194,043,000
Source: see text
Bactericidal Protein Treatment
Background
The application of biotechnology to mastitis treatment is opening up new 
avenues of prevention and control which may have important implications. These 
bacterocidins consist of enzymes and other bactericidal proteins. They act as catalysts 
and are very specific to a single chemical reaction. For mastitis treatment, 
bacterocidins can be either infused into the udder (in the same way as antibiotics) or 
used in solutions (such as teat dips). The general characteristics of this treatment are 
the same in both cases. Although most work to date has been done on enzymic 
proteins to control Staphylococcus aureus, research with bactericidal proteins against 
other organisms suggests that the conclusions drawn are general. The authors proceed 
therefore by extrapolation the research results to all mastitis-causing organisms.
Bacteroeidin lyse (kill) targeted organisms rapidly by damaging the cell wall. 
They are produced naturally by bacteria as a means of population control. These 
proteins are larger molecules than antibiotics and are expected to persist in the udder 
for longer periods of time. Unlike antibiotics, the rapid action of bacterocidins 
reduces the likelihood of an induced resistance in target and non-target organisms. In
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the longer term, however, resistance will develop and new bacterocidins will need to 
be identified.
Bacterocidins used for mastitis treatment are non-toxic to other organisms. 
This allows their inclusion into food products under FDA health regulations, which 
implies that treated lactating cows or dry cows which calve prematurely need not have 
their milk withheld, as would be the case with antibiotics in subclinical treatment.
Effectiveness
Early research results indicate that these bacterocidins are comparable to 
antibiotic treatment and twice as effective as penicillin treatment for first time 
infections in heifers. Combining bacterocidins and antibiotics produces a synergistic 
reaction which may prove very significant. Use of combinational bactericidal protein 
provides similar bacterial synergism. Treating cows with one of these combined 
products is likely to prove more effective. Combinations appear to require lower 
concentrations which may reduce expenses involved with treatment. The milk 
exclusion for such a product would require a shortened withholding of one day, as 
compared to 6.6 days with antibiotics. Milk would be withheld for very high SCCs 
(>1,000,000) or abnormal secretion but not due to toxicity.
The specificity of enzymes means that specific bacterocidins will have to be 
prescribed by veterinarians who are able to determine the organism causing the 
infection. This is in contrast to broad spectrum antibiotics which require no 
prescription for use to control mastitis. The cost of a veterinary diagnosis could make 
enzyme use non-cost-effective compared to antibiotics. However, the combination of 
bacterocidins into a single medication would allow the products to be sold as non­
prescription drugs. It is assumed the cost of the protein treatment will be similar to 
that of currently-used antibiotics to insure that the initial adoption will occur. 
Farmers must perceive this treatment method as economically competitive with
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antibiotic alternatives. The adoption of enzymes is expected to be slow initially until 
the treatment can be sold as a non-prescriptive drug. However, with new specific 
diagnosis such as Pro staph and Elisa incorporated into routine management, specific 
treatment may prove to be effective and affordable.
Implications
Replacing antibiotics with enzymes have the following expected effects on New 
York’s dairy industry:
Milk production per cow would increase slightly because treatment 
effectiveness is increased for first time infections. No data are yet available to 
estimate this impact. The cost of discarded milk is reduced from $9.08/cow to 
$1.38/cow when milk is withheld for only one day during treatment.
The cost of drugs is not anticipated to change. All current marketing 
investigations indicate that price competitiveness with antibiotics will be necessary for 
successful adoption. Bacterocidin administration should be similar to antibiotics.
Labor requirements are decreased slightly to the extent that first time 
infections can be treated effectively during lactation and eliminated.
Cow replacement costs are not anticipated to change.
The benefits for the processing sector can be captured very quickly. Milk will 
not be adulterated and testing will therefore be unnecessary. This saving should be 
attributed to the new treatment but cannot be quantified readily. Enhanced fat 
production will be modest and noticeable only to the degree that first time infections 
are eliminated. Losses in cheese manufacturing should not occur if no antibiotics are 
used. Enzymes are organism-specific and should not inhibit starter cultures and do 
not cause casein or fat decomposition.
Table 7 summarizes the effects on New York’s industry. On farm losses would 
be reduced by $7.70/cow/year or $6,606,600 for all of New York’s cows. Off farm
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losses would be reduced by $12,100,000. Proportionately, processors would benefit 
more (65%) compared to farmers (35%), It should therefore be expected that the milk 
processing industry will promote the use of enzymatic treatment for mastitis control.
These savings for New York State alone appear to be substantial enough to 
conclude that an effective bacterocidin treatment, which could be sold as a non­
prescription drug, could largely replace antibiotics nationwide. It is estimated that in 
the U.S. $25 million are spent annually on antibiotics to treat mastitis. Some 
antibiotics may still be used to achieve the synergistic effect but manufacturers of 
antibiotics would face significant cut backs in demand for use in the treatment of 
mastitis. Other groups concerned about the widespread introduction of antibiotics into 
the food chain would also be expected to support non-antibiotic substitution. 
Bactericidal protein however must be subjected to a full review by the FDA, USDA 
and other regulatory agencies prior to their commercial availability. This should be a 
relatively straight forward process as these proteins are naturally occurring. 
Biotechnology only provides an economical means of production. However the 
required development and testing means these products’ commercialization remains in 
the future.
Table 7: Summary of Economic Savings in New York as a Result of Bacterocidin
Treatment
On farm $ 6,606,600
Off farm $ 12,100,000
Total $ 18,706,600
Source: see text
Mastitis Vaccine
Background
Antibiotics and bacterocidins are useful predominantly to treat infected cows. 
Treatment implies a cow will have gone through a subclinical period, with the
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associated economic losses, before the infection becomes apparent and therapy is 
initiated. After treatment the cow is as susceptible as before and prevention of 
reinfection continues to be dependent on careful management practices.
For decades the search has been underway for an effective immunization 
against mastitis. The gland’s immune response presents a special problem in the type 
and levels of antibody able to cross into the udder, and the difficulty of determining 
antigens effective in stimulating resistance to the numerous udder pathogens have 
proven insurmountable. Recently, a new method for retaining the surface capsule of 
Staphylococcus aureus has been perfected that has been shown to be effective in both 
the laboratory and in a limited number of field trials. Cows immunized with a 
capsule-rich vaccine have heightened resistance to infection by that organism.
Effectiveness
To date, a vaccine has been shown effective only for Staphylococcus aureus, a 
leading source of contagious mastitis. This is an attractive target organism as it is 
possible to eliminate S. aureus from a herd. For the purpose of this analysis it is 
assumed that similarly effective vaccines can be developed for the other contagious 
and environmental forms of mastitis infection. Protection against environmental 
infection is particularly important as it cannot be eliminated from the environment. 
There is some concern opportunistic environmental bacteria will flourish in the 
absence of contagious forms although this has not necessarily been the case with S. 
aureus free herds.
Data on the effectiveness of the existing vaccine are limited due to the few 
field trials conducted to date. Laboratory trials do indicate increases in antibody 
titers and concomitant reductions in Field data interpretation is more
complicated than laboratory designs since field tests permit the cooperating dairyman 
to continue with normal management practices. In the highly infected herds typically
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used for these tests -- high to insure an adequate number of infected quarters to give 
meaningful results -- control is often limited and heavy culling is used routinely. 
Heavy culling combined with the introduction of mastitis-free animals means that the 
control group in a successful immunization test will understate the degree of infection 
in the initial population.
The data which are available suggest a decline in the bulk tank SCC of about 
150,000. (187,000 in the Norcross and Kenny te s t^ )  and 130,000 in the Norwegian 
trial^1^). In New York, using the 400,000 SCC average adopted above, the level would 
decline to about 250,000.
Implications
Loss reductions in the seven on-farm loss categories can be summarized as 
follows:
The decline in SCC level from 400,000 to 250,000 corresponds to a reduction in 
production loss of about 2% (Table A-l). In terms of linear scores, the improvement is 
from 5 to about 4 (Table A-2). This corresponds to an increase in milk production per 
cow of 250 pounds a year, or $29.30 at $11.72/cwt*. For all of New York this saving 
is $25,139,400.
The increase in antigen production is expected to prevent new infections and 
reduce clinical signs. Since only clinical cases need be treated with antibiotics, no 
milk should have to be discarded. Vaccination can produce an elevated SCC level for 
the first two days following administration, but the levels are not sufficiently high to 
necessitate discarding milk. For practical application and best response, vaccination is 
recommended just prior to calving. This provides protection during a high risk period 
and when SCC are not of concern. The savings are estimated at $9.08 per cow or 
$7,790,640 for New York State.
*Based on year (365 days to 240 lactation days) adjustment and assuming a herd of 
25% first year and 75% second and beyond lactation cows.
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The costs of veterinary services, drug costs and labor are not expected to 
change on average. The costs of the vaccines are not known at this time, but they 
must be competitive with existing products to be viable in the low-profit dairy sector. 
The rate of culling is likely to decrease through the prevention of new infection and 
fewer clinical cases. However, since the magnitude of such a shift is uncertain it is 
not quantified here.
Off-farm loss reductions will also be substantial. With a SCC level of 250,000, 
fat losses during milk processing should decline from 3.5% to about 2.75%, or for the 
New York herd from 19,350,000 pounds to 15,000,000 pounds. Adjusting milk prices 
for the butterfat differential with 3.69% butterfat gives a price of $11.77/cwt, or 5C 
higher. At 11,884,751,000 pounds of milk produced in New York this is a $5,900,000 
gain.
Reduced infection and clinical cases will reduce the use of antibiotics,
effectively increasing cheese yields. The same gains as for the enzyme technology are
assumed, namely $10.35. These figures are summarized in Table 8 and give a total
annual savings of $51 million. In this case farmers would benefit much more than
processors - roughly 65% versus 35%. Savings due to immunization are more than 2.5
times the savings associated with the bacterocidin treatment and reflect the potential
of an effective low cost vaccination. However, due to the preliminary nature of
vaccine production, these figures must be considered as very tentative.
Table 8: Summary of Economic Savings in 1988 for New York as a Result of Mastitis 
Vaccinations
On Farm
Increased milk production 
Discarded milk
$ 25,139,400 
7,790,640
Off Farm
Elimination of milk adulteration 
Increased fat composition 
Increased production
1.750.000
5.900.000 
10.350.000 
50,930,040TOTAL
Source: see text
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Summary and Conclusions
Mastitis clearly remains a major cost to the New York dairy industry. 
Available data suggest a sub-clinical infection level of about 50 percent. At these 
levels of infection the costs of lost milk production are substantial — an estimated 
$143 per cow in 1988. Including all costs associated with clinical infections the 
amount rises to about $177 per cow annually, or $150 million for New York state. 
When associated losses at the processing level are added the total approaches $200 
million annually.
A literature survey suggests costs have remained near this level for some time, 
due largely to the limited advances in treatment over the past score of years. Two 
approaches are dominant: hygienic management practices including "dry cow" 
treatment at the end of the lactation cycle, and antibiotic treatment during the 
milking cycle. The latter case requires milk be withheld from human consumption. 
When milk is inadvertently shipped, the processing industry suffers losses. But even 
sub-clinical levels of mastitis degregate the quality of the milk and lead to lower 
cheese yields.
In this environment, technological enhancements are much in demand. Two 
new approaches have recently been developed and been demonstrated as effective in 
preliminary field trials. These developments are (1) bactericidal protein treatments 
and (2) an immunization vaccine. Available data suggest potential savings of $18.7 
and $50.9 million annually respectively for the two approaches. These estimates are 
very preliminary and any number of factors may arise which could reduce the 
economic returns. One of these factors is the price of the medication itself. But the 
potential benefits are so substantial that even some technological advance would be a 
major benefit to New York’s dairy sector.
These estimates are based on the new products supplementing existing practices. 
No product is likely to replace the need for careful herd hygiene so that any decline
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in careful management practices is likely to negate much of the value of the new 
products. But, viewed in this environment, the new products are promising additions 
to the currently available strategies for dealing with the problems of mastitis.
The products, as applied to date, have clear and readily apparent benefits to 
dairymen. They require no major changes in management practices. Past experience 
has shown that products with these characteristics are adopted relatively rapidly. 
Thus the benefits of these products are likely to be seen soon after commercial release. 
The total savings appear to be much greater when adopting the vaccination treatment. 
However the distribution of benefits between farmers and processors is very different. 
One potentially complicating factor is the portion of the benefits from bacterocidin 
use which accrues to milk processors. Processors will have an incentive to see that 
these control products are used but no direct involvement in the adoption decision. 
Adjustments in product pricing which pass part of the processors’ benefits back to 
producers can be helpful in spurring more rapid adoption of these products.
The timing of market readiness for these new products is very uncertain at this 
point In cases of both the bacterocidins and the vaccination are directed at only one 
of the four major sources of mastitis. To be economically effective all or most 
common bacteria must be controlled by such products. Early results suggest the other 
forms of bacteria can be controlled in a similar fashion. Nevertheless, even under the 
most optimistic scenario, it will be a number of years before all the necessary products 
are developed, the regulatory requirements satisfied and production initiated. Five 
years would appear to be a minimum time required, at least in the U.S., and a full 
decade is possible. At that time the dairy sector will have available a significant cost- 
reducing product, but not one which is likely to have profound ramifications on the 
structure and location of milk production in the United States.
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APPENDIX
Relationship Between Infection Levels and Lost Milk Production
Table A-l:
Relationship between CMT. SCC and decrease in milk production
CMT SCC Lost milk production
140.000
165.000 5%
195.000
225.000
260.000
Trace 300,000 8%
340.000
380.000
420.000
465.000
515.000
565.000
620.000 9%
675.000
730.000 to
790.000
855.000 18%
920.000
990.000
1.055.000
1.130.000
1.200.000
1,280,000
1.360.000
1.440.000 19%
1.525.000
1.610.000 to
2 1,700,000
1,800,000 25%
1.920.000
2.030.000
2.180.000 
2,280,000
Source: adapted from 30
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Table A-2:
Relationship between Linear Score. SCC and annual lost milk production
Lbs of milk lost relative 
Linear Score SCC to linear score -  2
heifers 2+lactation
0 12,500
1 25,000
2 50,000
3 100,000 200 400
4 200,000 400 800
5 400,000 600 1,200
6 800,000 800 1,600
7 1,600,000 1,000 2,000
8 3,200,000 1,200 2,400
9 6,400,000 1,400 2,800
Source: adapted from 36
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